European shares gain on oil sector, earnings boost
For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window
Oil and gas stocks gain amid Middle East conflict
Philips soars on Q2 earnings beat
Heineken down after operating profit growth miss
Updated at 0832 GMT
By Pranav Kashyap
July 29 (Reuters) -European shares started the week strong, lifted by global oil gains amid Middle East conflict fears and a slew of upbeat earnings, though a drop in Reckitt tempered the rally.
The pan-European STOXX 600 index .STOXX edged up 0.3%, as of 0832 GMT on Monday, after the benchmark posted marginal gains last week.
Oil and gas stocks .SXEP were on top, gaining 1.4%, as crude prices inched higher following a rocket strike in the Israeli-occupied Golan Heights. O/R
Meanwhile, investors braced for a bustling week, with attention shifting to the U.S. as four of the 'Magnificent 7' companies report, poised to significantly influence market sentiment.
The U.S. Federal Reserve's policy meeting is on Wednesday where traders are wagering the central bank will lay the groundwork for a September rate cut.
"This week could very well end up setting the tone for the rest of the summer because we're going to learn how central banks are thinking about the trade offs they're facing," said Arun Sai, senior multi-asset strategist at Pictet Asset Management.
Investors were on guard as a global tech selloff was sparked last week when results from Tesla TSLA.O and Alphabet GOOGL.O failed to impress markets.
"If we went into this earnings season expecting the same kind of beats that we had the last three or four quarters - we are in for some disappointment. We got a little bit of that last week and we're not out of the woods yet," Sai said.
Among individual stocks, Philips PHG.AS soared 10.3% after the Dutch medical devices maker reported an estimate-beating quarterly result, boosted by higher earnings and the implementation of its restructuring programme.
Shares of Germany's Merck MRCG.DE were up 3.3% after the company raised its forecast for the group, mainly driven by a strong operating performance at its healthcare and electronics units.
Keeping gains in check, Reckitt Benckiser RKT.L slumped 9% as close to multiple lawsuits have been filed in the U.S. against the Enfamil formula maker and Abbott Laboratories ABT.N.
A jury on Friday found that Abbott's specialized formula for premature infants caused an Illinois girl to develop a dangerous bowel disease, ordering the healthcare company to pay $495 million in damages.
Heineken HEIN.AS lost 7% after the Dutch brewer missed estimates for half-year operating profit growth, even as it raised its full-year profit outlook. Peer Carlsberg CARLb.CO lost 4%.
Reporting by Pranav Kashyap in Bengaluru; Editing by Sherry Jacob-Phillips and Mrigank Dhaniwala
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
